183 related articles for article (PubMed ID: 31088315)
1. Regulation of
Zhu Q; Yu L; Qin Z; Chen L; Hu H; Zheng X; Zeng S
Epigenetics; 2019 Aug; 14(8):791-803. PubMed ID: 31088315
[TBL] [Abstract][Full Text] [Related]
2. The failure of DAC to induce OCT2 expression and its remission by hemoglobin-based nanocarriers under hypoxia in renal cell carcinoma.
Chen L; Wang Z; Xu Q; Liu Y; Chen L; Guo S; Wang H; Zeng K; Liu J; Zeng S; Yu L
Theranostics; 2020; 10(8):3562-3578. PubMed ID: 32206108
[No Abstract] [Full Text] [Related]
3. Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin.
Liu Y; Zheng X; Yu Q; Wang H; Tan F; Zhu Q; Yuan L; Jiang H; Yu L; Zeng S
Sci Transl Med; 2016 Jul; 8(348):348ra97. PubMed ID: 27440728
[TBL] [Abstract][Full Text] [Related]
4. Elevated histone H3 acetylation and loss of the Sp1-HDAC1 complex de-repress the GM2-synthase gene in renal cell carcinoma.
Banerjee A; Mahata B; Dhir A; Mandal TK; Biswas K
J Biol Chem; 2019 Jan; 294(3):1005-1018. PubMed ID: 30463940
[TBL] [Abstract][Full Text] [Related]
5. Histone H3 Lysine 4 Trimethylation, Lysine 27 Trimethylation, and Lysine 27 Acetylation Contribute to the Transcriptional Repression of Solute Carrier Family 47 Member 2 in Renal Cell Carcinoma.
Yu Q; Liu Y; Zheng X; Zhu Q; Shen Z; Wang H; He H; Lin N; Jiang H; Yu L; Zeng S
Drug Metab Dispos; 2017 Jan; 45(1):109-117. PubMed ID: 27821436
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic regulation of microRNA expression in renal cell carcinoma.
Schiffgen M; Schmidt DH; von Rücker A; Müller SC; Ellinger J
Biochem Biophys Res Commun; 2013 Jun; 436(1):79-84. PubMed ID: 23707942
[TBL] [Abstract][Full Text] [Related]
7. Expression and epigenetic regulatory mechanism of BNIP3 in clear cell renal cell carcinoma.
Shao Y; Liu Z; Liu J; Wang H; Huang L; Lin T; Liu J; Wei Q; Zeng H; He G; Li X
Int J Oncol; 2019 Jan; 54(1):348-360. PubMed ID: 30365137
[TBL] [Abstract][Full Text] [Related]
8. Lactate Increases Renal Cell Carcinoma Aggressiveness through Sirtuin 1-Dependent Epithelial Mesenchymal Transition Axis Regulation.
Miranda-Gonçalves V; Lameirinhas A; Macedo-Silva C; Lobo J; C Dias P; Ferreira V; Henrique R; Jerónimo C
Cells; 2020 Apr; 9(4):. PubMed ID: 32340156
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma.
Wang Y; Zhu Q; Hu H; Zhu H; Yang B; He Q; Yu L; Zeng S
Biochem Pharmacol; 2021 Jun; 188():114546. PubMed ID: 33838133
[TBL] [Abstract][Full Text] [Related]
10. Resistance after chronic application of the HDAC-inhibitor valproic acid is associated with elevated Akt activation in renal cell carcinoma in vivo.
Juengel E; Makarević J; Tsaur I; Bartsch G; Nelson K; Haferkamp A; Blaheta RA
PLoS One; 2013; 8(1):e53100. PubMed ID: 23372654
[TBL] [Abstract][Full Text] [Related]
11. HDAC7 regulates histone 3 lysine 27 acetylation and transcriptional activity at super-enhancer-associated genes in breast cancer stem cells.
Caslini C; Hong S; Ban YJ; Chen XS; Ince TA
Oncogene; 2019 Sep; 38(39):6599-6614. PubMed ID: 31375747
[TBL] [Abstract][Full Text] [Related]
12. Global histone acetylation levels: prognostic relevance in patients with renal cell carcinoma.
Mosashvilli D; Kahl P; Mertens C; Holzapfel S; Rogenhofer S; Hauser S; Büttner R; Von Ruecker A; Müller SC; Ellinger J
Cancer Sci; 2010 Dec; 101(12):2664-9. PubMed ID: 20825416
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma.
Wang XF; Qian DZ; Ren M; Kato Y; Wei Y; Zhang L; Fansler Z; Clark D; Nakanishi O; Pili R
Clin Cancer Res; 2005 May; 11(9):3535-42. PubMed ID: 15867257
[TBL] [Abstract][Full Text] [Related]
14. Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma.
Morris MR; Gentle D; Abdulrahman M; Maina EN; Gupta K; Banks RE; Wiesener MS; Kishida T; Yao M; Teh B; Latif F; Maher ER
Cancer Res; 2005 Jun; 65(11):4598-606. PubMed ID: 15930277
[TBL] [Abstract][Full Text] [Related]
15. Relevance of copper transporter 1 and organic cation transporters 1-3 for oxaliplatin uptake and drug resistance in colorectal cancer cells.
Buß I; Hamacher A; Sarin N; Kassack MU; Kalayda GV
Metallomics; 2018 Mar; 10(3):414-425. PubMed ID: 29417972
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of miR-489-3p and miR-630 inhibits oxaliplatin uptake in renal cell carcinoma by targeting OCT2.
Chen L; Chen L; Qin Z; Lei J; Ye S; Zeng K; Wang H; Ying M; Gao J; Zeng S; Yu L
Acta Pharm Sin B; 2019 Sep; 9(5):1008-1020. PubMed ID: 31649850
[TBL] [Abstract][Full Text] [Related]
17. The epigenetic modifier CHD5 functions as a novel tumor suppressor for renal cell carcinoma and is predominantly inactivated by promoter CpG methylation.
Du Z; Li L; Huang X; Jin J; Huang S; Zhang Q; Tao Q
Oncotarget; 2016 Apr; 7(16):21618-30. PubMed ID: 26943038
[TBL] [Abstract][Full Text] [Related]
18. BRD4 promotes gastric cancer progression through the transcriptional and epigenetic regulation of c-MYC.
Ba M; Long H; Yan Z; Wang S; Wu Y; Tu Y; Gong Y; Cui S
J Cell Biochem; 2018 Jan; 119(1):973-982. PubMed ID: 28681984
[TBL] [Abstract][Full Text] [Related]
19. pVHL-mediated transcriptional repression of c-Myc by recruitment of histone deacetylases.
Hwang IY; Roe JS; Seol JH; Kim HR; Cho EJ; Youn HD
Mol Cells; 2012 Feb; 33(2):195-201. PubMed ID: 22286234
[TBL] [Abstract][Full Text] [Related]
20. HDAC1-induced epigenetic silencing of ASPP2 promotes cell motility, tumour growth and drug resistance in renal cell carcinoma.
Li H; Wang X; Zhang C; Cheng Y; Yu M; Zhao K; Ge W; Cai A; Zhang Y; Han F; Hu Y
Cancer Lett; 2018 Sep; 432():121-131. PubMed ID: 29890207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
